Safety and Efficacy of CD10367 in Psoriasis Vulgaris

Psoriasis Vulgaris Clinical Trial

Official title: Exploratory Study to Evaluate the Safety and Efficacy of CD10367 in Subjects With Psoriasis

Status Completed

Clinical Trial Summary

This is an exploratory, single-centre, investigator blinded, randomized, controlled, intra-individual study, involving subjects with psoriasis vulgaris.

The objective is to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once daily application.

Clinical Trial Description

Study drugs will be applied in each subject once daily, 5 days a week during the first 2 weeks and for 4 days the third week on 6 mini-zones located on at least 2 psoriatic plaques as described below:

• on 2 mini-zones pretreated by a keratolytic product, will be tested:

• CD10367 3% solution

• CD10367 solution placebo

• on 4 mini-zones non-pretreated, will be tested:

• CD10367 3% solution

• CD10367 1% solution

• CD10367 solution placebo

• Betneval 0.1% ointment ;

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

• NCT number: NCT03025282
• Study type: Interventional
• Source: Galderma R&D
• Status: Completed
• Phase: Phase 2
• Start date: November 3, 2016
• Completion date: March 24, 2017